Johnson & Johnson (NYSE: JNJ) today announced new long-term data from the QUASAR long-term extension (LTE) study showing that TREMFYA® (guselkumab) sustained clinical, endoscopic, and histologic ...
Medications for ulcerative colitis (UC) can treat and prevent flares, but they can also come with some uncomfortable side effects. For example, immunomodulators like azathioprine (Azasan) decrease UC ...
What Is Infusion for Ulcerative Colitis? If your doctor has recommended infusion therapy, this is probably because standard treatment hasn’t helped relieve symptoms caused by moderate-to-severe ...
How Does Tremfya Work for Ulcerative Colitis? Tremfya is a monoclonal antibody that reduces inflammation. The main ingredient in Tremfya is a medicine called guselkumab. This medicine blocks a ...
An experimental monoclonal antibody treatment appears to ease the digestive disorder ulcerative colitis in patients who've failed other medications, a new trial shows. The treatment, tulisokibart, ...
More than a quarter of patients with ulcerative colitis do not receive prior advanced therapy before initiating mirikizumab, ...
People living with the pain, bloody diarrhea and sometimes urgent need to use the toilet that comes with ulcerative colitis may soon have a new treatment option that's already been given the go-ahead ...
Ulcerative Colitis Market grows at 5.4% CAGR (2025–2033), reaching US$ 12.79 Billion on rising biologic adoption, biosimilars, and personalized IBD therapies. North America leads the ulcerative ...
Researchers at Örebro University have identified blood markers that can indicate who is at risk of developing ulcerative ...
Ulcerative colitis, a type of inflammatory bowel disease (IBD), is marked by periods of remission times when you experience few, if any symptoms followed by relapses caused by active inflammation, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results